What We Know About GLP-1 and Cancer Risk

• Current research shows no confirmed link between GLP-1 medications and increased cancer risk in humans.
• Some studies suggest potential protective effects, especially for certain hormone-related and obesity-related cancers.
• When prescribed and monitored by professionals, GLP-1 treatments remain a safe, evidence-based option for metabolic and weight management support.

Understanding GLP-1 Medications and How They Work

GLP-1 medications, also known as GLP-1 receptor agonists, were originally developed to help manage type 2 diabetes. Over time, research revealed that these medications also support healthy weight regulation, appetite control, improved metabolic balance, and other benefits.

GLP-1 is a hormone naturally produced in the gut. After eating, your body releases GLP-1 to help manage blood sugar by prompting the pancreas to release insulin and slowing digestion. This process helps regulate hunger, improve satiety, and stabilize energy levels throughout the day.

When taken as medication, GLP-1 receptor agonists, like Ozempic®, Wegovy®, or Mounjaro™, mimic the effects of the body’s natural GLP-1 hormone. They help reduce post-meal blood sugar spikes, promote a feeling of fullness, and encourage more mindful eating patterns.

Because these medications act on the same receptors involved in insulin and metabolism, they have been shown to improve several markers of metabolic health, including insulin sensitivity, A1C levels, and body composition. 

This connection between GLP-1 activity and hormonal regulation is also where early discussions about potential uses and side effects.

Why People Are Asking About GLP-1 and Cancer Risk

As GLP-1 medications like Ozempic and Wegovy have become more widely used, questions have emerged about their long-term safety, particularly around cancer risk. 

Much of this concern began with early animal studies that showed thyroid cell changes in rodents given very high doses of GLP-1 receptor agonists. These findings led researchers to investigate whether the same effects could occur in humans.

It’s important to understand that rodent thyroid tissue responds differently to GLP-1 stimulation than human tissue does. So far, large clinical trials and post-marketing studies in people have not shown a confirmed link between GLP-1 use and cancer. However, these medications are relatively new for widespread use, so researchers continue to monitor long-term data closely.

Social media has also played a role in amplifying worry. Posts that highlight isolated findings without context can spread quickly, which creates confusion or unnecessary fear. In reality, the majority of current evidence supports the overall safety of GLP-1 medications when prescribed and monitored appropriately.

Does GLP-1 Increase Cancer Risk?

As GLP-1 medications become more widely used, researchers are examining long-term safety, including whether these drugs might influence cancer risk. Recent evidence offers helpful clarity.

A 2025 Danish study in The Lancet Regional Health Europe used a nationwide emulated trial, analyzing decades of prescription and health data. Nearly 40,000 adults starting GLP-1 medications were compared with users of another diabetes treatment (DPP-4 inhibitors).

After ten years, researchers saw a slight increase in overall cancer diagnoses among continuous GLP-1 users — about four extra cases per 100 people. However, there was no increase in cancer or death combined, and GLP-1 users actually had fewer deaths overall. This suggests a survival advantage: users may live longer, leaving more time for unrelated cancers to appear in records.

By contrast, a 2025 JAMA Oncology study of more than 86,000 adults with obesity found a 17% lower overall cancer risk among GLP-1 users. Strongest protective effects were seen in endometrial, ovarian, and meningioma cancers. A small, non-significant rise in kidney cancer will need more study.

Similar findings were presented at the 2025 American Society of Clinical Oncology (ASCO) meeting, following 170,000 adults with obesity and diabetes. Those using GLP-1 medications had a modestly lower risk of several obesity-related cancers, including colon and rectal cancer. Women appeared to benefit most.

Overall, there is no clear evidence that GLP-1 medications cause cancer. Several large studies suggest they may even reduce risk for certain types. More long-term research is needed, but current data supports GLP-1 safety when prescribed and monitored appropriately.

Factors That Influence Cancer Risk Beyond GLP-1

Cancer risk is influenced by a wide range of interconnected factors, not just one medication or lifestyle choice. Understanding the bigger picture can help you take proactive steps toward long-term wellness.

Some of the most important factors that shape cancer risk include:

• Genetics and family history. Certain inherited traits can increase susceptibility to specific cancers, though healthy habits still play a major protective role.
• Chronic inflammation. Persistent low-grade inflammation can promote cellular stress and DNA damage over time.
• Insulin resistance and metabolic imbalance. Elevated insulin and blood sugar levels have been linked to increased risk for several cancers. GLP-1 medications help correct these imbalances.
• Excess body fat. Fat tissue releases inflammatory and hormonal signals that can affect cell growth and repair. Sustainable weight loss can help lower this risk.
• Hormonal fluctuations. Estrogen, insulin, and growth hormones all interact in ways that influence cancer risk, particularly in women.
• Lifestyle factors. Nutrition, movement, sleep, and stress levels all play a key role in regulating inflammation and supporting healthy immune function.

How to Discuss GLP-1 Safety With Your Healthcare Provider

If you’re considering GLP-1 treatment or are currently using one, it’s completely normal to have questions, especially when you see headlines about safety or long-term effects. The most important thing you can do is have open, informed conversations with a qualified healthcare provider who understands your full health picture.

Your provider can help you:

• Review your medical history to identify any personal or family factors that may influence treatment safety.
• Discuss your goals, whether you want to use Ozempic for weight loss, appetite control, metabolic health, or diabetes support.
• Evaluate potential risks and benefits based on your unique health profile.
• Develop a monitoring plan that includes lab work, follow-up visits, and symptom tracking to ensure your treatment remains safe and effective.
• Adjust your care plan over time as your body and goals evolve.

It’s also helpful to ask direct questions during your visit, such as:

• “Am I a good candidate for GLP-1 medication based on my medical history?”

• “What GLP-1 side effects should I watch for and how can we manage them if they occur?”

• “How will we track my progress and monitor for any potential complications?”

• “Are there alternative options if GLP-1 therapy isn’t right for me?”

Navigate GLP-1 Treatment With the Right Guidance

The latest research on GLP-1 and cancer risk is reassuring, as no clear link has been found. Some studies even suggest potential protective benefits.

Still, these medications work best under medical supervision. A qualified provider can personalize your plan, monitor safety, and help you reach your health goals with confidence.

At Kintsu MedSpa & Wellness, we take a science-based, holistic approach to care. Every plan is designed to support your metabolism, hormones, and long-term wellness safely and sustainably.

Ready to learn more? Book an appointment with Kintsu MedSpa & Wellness to discover if GLP-1 therapy is the right fit for your health and lifestyle.